B
Bright Minds Biosciences
Biotech & Life Sciences · New York City, United States · Founded 2017 · IPO 2021
Biotechnology company creating the next generation of psychedelics to treat mental health and other CNS disorders MoreLess
Bright Minds Bio is a biotechnology company focused on developing next-generation therapeutics aimed at improving the lives of patients suffering from severe and life-altering brain diseases. The company leverages its extensive experience in the biology of the serotonergic system to create highly targeted drugs that address specific patient populations unmet by current treatments.
Bright Minds Bio operates in the pharmaceutical and biotechnology market, primarily serving patients with conditions such as pain, seizures, and neuropsychiatric disorders. The company's business model revolves around drug discovery and development, where it creates new chemical entities (NCEs) and modifies existing molecules to enhance therapeutic properties while minimizing side effects.
Revenue is generated through the development and commercialization of these specialized drugs, often in partnership with larger pharmaceutical companies or through direct sales. The company also benefits from intellectual property rights and potential milestone payments and royalties from licensing agreements.
Keywords: biotechnology, serotonergic drugs, brain diseases, pain management, seizures, neuropsychiatric disorders, drug discovery, therapeutics, pharmaceutical, NCEs.
Company overview
Bright Minds Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- New York City, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 53.8
Valuation & funding
Bright Minds Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | May 2026 | $0 | — | B Group | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2026 | $100M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VC✓Equity / VC | Oct 2024 | $35M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Dec 2023 | $900K | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VC✓Equity / VC | Dec 2022 | $2M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Aug 2022 | Undisclosed | ↗ | ||
| IPO✓Exit | Feb 2021 | Undisclosed | — | ||
| SEED✓Equity / VC | Nov 2020 | Undisclosed | — | ||
| SPINOUT✓Other financing | Nov 2017 | University of Illinois Urbana Champaign | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Bright Minds Biosciences website traffic
Latest recorded traffic for Bright Minds Biosciences is 4K monthly website visits, down 9.1% over the last three months. Bright Minds Biosciences's team grew 22.2% over the past year.
Comparisons
Bright Minds Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Bright Minds Biosciences's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Bright Minds Biosciences's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Bright Minds Biosciences has talent and traffic
team presence
In the news
Latest news about Bright Minds Biosciences
Recent press, funding announcements, and product moves mentioning Bright Minds Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Bright Minds Biosciences
An AI-synthesized read of the highest-engagement posts about Bright Minds Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bright Minds Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.